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Abstract
Introduction. Biobanks are a valuable resource for creating advancements in science through
cutting-edge omics research. Twin research methods allow us to understand the degree to
which genetics and environmental factors contribute to health outcomes.
Methods. The Sri Lankan Twin Registry biobank (SLTR-b) was established in 2015 as part of
Colombo Twin and Singleton Follow-up Study. Venous blood and urine were collected from
twins and comparative sample of singletons for clinical investigations and biobanking.
Results. The SLTR-b currently houses 3369 DNA and serum samples. Biobank specimens are
linked to longitudinal questionnaire data, clinical investigations, anthropometric measure-
ments, and other data.
Discussion. The SLTR-b aims to address gaps in health and genetics research. It will provide
opportunities for academic collaborations, local and international, and capacity building of
future research leaders in twin and omics research. This paper provides a cohort profile of
the SLTR-b and its linked data, and an overview of the strategies used for biobanking.
Introduction
Twin research methods are genetically sensitive designs which allow researchers to understand
the degree to which genetics and environmental factors contribute to variation (individual dif-
ferences) in variables such as health outcomes. In addition, twin studies allow for associations
between traits (disorders) to be quantified in parts due to shared genes and shared environ-
mental factors.
Materials and methods
The Sri Lankan Twin Registry was established in 1997, and is the first ever twin register in
South Asia [1]. It is still one of the few large-scale functional population-based twin registries
in the developing world [2]. In 2007, twins from the registry and a comparative sample of sin-
gletons (non-twins) were recruited from Colombo district to conduct a cross-sectional study
on mental health titled ‘The Colombo Twin and Singleton Study’ (COTASS 1) [3]. The
study was a collaboration between the Institute for Research and Development, Colombo,
Sri Lanka (IRD), the Institute of Psychiatry, Psychology and Neuroscience, Kings College
London, UK, and Brain and Mind Centre, University of Sydney, Australia. COTASS 1
aimed to bridge a gap in genetic research on mental health in a low- and middle-income coun-
try by exploring the genetic and environmental factors involved in common mental disorders
in the Sri Lankan population.
The same cohort was revisited in 2012 to conduct a multi-component study on mental
health, metabolic syndrome factors, and other health and well-being variables (the Colombo
Twin and Singleton follow-up Study – COTASS 2) [4]. The Sri Lankan Twin Registry biobank
(SLTR-b) was established as a component of COTASS 2 with the aim to foster innovative epi-
demiological research. Participant recruitment lasted until the end of December 2015 for all
components.
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Setting
The COTASS cohort is based in the Colombo district which is a
multi-ethnic and multicultural city [5]. Although being the coun-
try’s capital, it is also the administrative and economic centre of
the country. It is the most highly populated district in Sri
Lanka with 2.4 million people comprising 11.4% of the country’s
population. Colombo has a mix of urban and rural areas with the
majority being urban. The district is heavily urbanised and more
westernised than other areas of Sri Lanka. The population is char-
acterised by great socio-economic diversity in terms of education,
employment, and occupational social class.
COTASS 2 comprised of three main study components: sur-
veys, anthropometric measures, and biospecimen collection for
clinical investigations and biobanking. This report is an overview
of the outcomes, and proceedings of collecting, processing, and
storing biospecimen data for the SLTR-b.
Minimising pre-analytical errors
Pre-analytical errors to ensure accurate laboratory results were
minimised through careful collection and handling of biospeci-
mens [6]. Similar care was taken with biospecimens collected
for long-term storage for biobanking such that they would be
usable for future downstream processes. A 4-h time frame for
biospecimen collection and transportation back to the laboratory
was maintained to reduce serum protein concentrations change
over time [7, 8]. Pre-printed stickers with participant’s unique
identification number were used to label collected samples
thereby avoiding unreadable or incorrectly written identification
numbers. Standard operating procedures for biospecimen collec-
tion, storage, and participant preparation instructions for biospe-
cimen collection were developed and optimised during the pilot
phase. These minimised variations as biospecimens were collected
from multiple sites which included clinical collection centres and
house visits.
As infection, inflammatory processes, and medications may
influence the outcome of certain blood investigations [9], partici-
pants were excluded from the clinical investigations’ component if
they (1) were on long-term medication which could interfere with
the parameters under the study (e.g. steroids or other immuno-
modulatory agents); or (2) suffered from a comorbid inflamma-
tory disease (e.g. chronic infections and autoimmune diseases).
Pregnant participants and those suffering from an acute ailment
or infection were revisited after delivery or recovery of illness,
respectively.
Biospecimen collection
Overnight fasting blood and first morning mid-stream urine was
collected contemporaneously from a single participant to measure
a variety of clinical investigations and for biobanking (see Table 1
for details). Blood was collected using a vacuum extraction tube
system (Becton Dickinson & Co Vacutainer System). Table 1 pro-
vides details of the collection order, preservative type, and
volumes. Clinical investigations were outsourced to a private
hospital in Colombo, housing an accredited laboratory.
Participants were given the options of (1) visiting the IRD; (2)
visiting the main collection centre of the private hospital or one of
their collection centres; or (3) have a research team visit their
homes for biospecimen collection. Home visits were chosen by
the majority of participants. The two teams conducting field
biospecimen collection included a phlebotomist and two research
assistants; one of whom had a medical background and the other
in charge of driving and navigation. A single team was able to visit
between 10 and 15 participants on a single day in the morning.
Participants were grouped into clusters based on their geographic
proximity to each other. Therefore, each participant’s overnight
fasting time remained between 9 and 12 h. Passive containers
with plastic transport racks stored inside rigifoam boxes layered
with coolant gel packs were used for specimen transportation.
Biospecimens collected from the satellite centres as well as at
the IRD and by the research teams were transported directly to
the main laboratory of the private hospital within the strict 4-h
time frame.
Processing of biospecimens for clinical investigations and
biobanking
Blood and urine samples intended for clinical investigations were
processed by staff at the main laboratory. Blood and urine not
used in clinical investigations was discarded. The 5 ml clot
activator tubes were centrifuged and the separated serum
(approximately 1.5–2 ml) was immediately divided into two
equal aliquots. These were transferred into screw-top cryogenic
vials using micropipettes and stored in a −80 °C freezer until
further testing.
Guidelines for biobanking standards have not been devel-
oped for Sri Lanka as yet. Therefore, we adopted several inter-
national guidelines to ensure integrity and viability of DNA
samples. DNA extraction from the whole blood samples was
carried out at IRD’s genetics laboratory using a Flexi Gene
250 DNA Purification Kit (Qiagen, Germany) under sterile
conditions. DNA of each participant was divided into two
equal aliquots and stored in 1.4 ml cryo-vials. The paired ali-
quots were stored in separate cryo-boxes and transferred back
to the −80 °C freezer.
The quality/purity of the extracted DNA were controlled by
measuring the absorbance (A) of every sample at 260, 280,
and 230 nm spectrophotometrically and determining the A260/
A280 and A260/A230 ratios. For samples of good quality, A260/
A280 is expected to lie in the range of 1.6–2.1. Lower values
may indicate protein contamination whereas higher values
may indicate a high content of RNA. At SLTR-b, the average
ratio A260/A280 in general is found to be 1.8 (±0.2). The A260/
A230 ratio was used as a secondary measure of DNA purity.
Expected A260/A230 values for pure DNA are commonly within
the range between 2.0 and 2.2. If the ratio is lower than
expected, it may indicate the presence of contaminants such
as proteins, Guanidine HCL (used for DNA extraction),
EDTA, salts, or phenols. At SLTR-b, the average A260/A230
ratio is found to be 2.0 (±0.2). Integrity of DNA samples was
assessed by agarose gel electrophoresis.
Clinical investigation reports
Original reports for clinical investigations were sent to partici-
pants whereas a digital copy was securely stored at IRD. We pro-
vided a cover letter which matched the participant’s name to the
identification number in the investigation reports. Body mass
index (BMI), waist circumference, and blood pressure were
included in this letter.
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Biospecimen storage
Biobanking samples were labelled using cryogenic labels and
stored in a large capacity −80 °C Forma 88600V freezer
(Thermo Fisher Scientific, USA). A strictly controlled temperature
is maintained to avoid unnecessary freeze–thaw cycles which may
affect the levels of serum biomarkers [10] or yield of extracted
genomic DNA [11]. During the biospecimen collection period,
the freezer was initially stored in the main laboratory, which
had backup generators and 24-h surveillance. The freezer was
locked, and contents only accessible to authorised personnel of
the COTASS 2 team.
In 2017, the −80 °C freezer and its content were transferred to
the IRD’s genetics laboratory while ensuring reliable power
backup and greater security. A generator powered backup system
was installed at IRD premises to ensure an uninterrupted power
supply. It was coupled with a GSM power failure alarming system
to alert the function of the power backup system using mobile
short messenger service notifications.
Ethics and governance
COTASS 2 received ethical approval from the Faculty of Medical
Sciences University of Sri Jayewardenepura, Sri Lanka Ethical
Review Committee (reference number: 596/11), and the
Psychiatry, Nursing & Midwifery Research Ethics Subcommittee,
King’s College London, UK (reference number: PNM/10/11-124).
Data collection procedures and storage of biospecimens were in
accordance with ethical standards of both institutional review
boards, the ethical policies and practices of the IRD [12], and
with the Helsinki Declaration of 1975. Informed written consent
from all participants were obtained using two sections in the same
form; one for each of the components of the main study including
clinical investigations, and another section specifically designed
for long-term storage of serum and DNA. Participants were
over 18 years of age and could opt out of any or all of the com-
ponents of COTASS 2. Participants were able to consent to (1)
clinical investigations only, (2) DNA and serum storage for bio-
banking only, or (3) both clinical investigations and biobanking.
Respondents visiting the IRD for biospecimen collection were
provided with a simple meal to break their fast after sample col-
lection. The main laboratory of the private hospital was provided
with only the participants’ unique identification number, age, and
gender to maintain anonymity and confidentiality. Participants
with clinical investigations indicating any departures from the
norm were advised to seek medical attention from the health cen-
tre nearest to them. The wide range of clinical investigations were
a great benefit to many, who were attending diabetic or cardiovas-
cular disease clinics. Ethical considerations for stored biospeci-
mens are mentioned in the discussion section.
Results
Biospecimen collection was completed by the end of December
2014. DNA extractions were completed in February 2016, follow-
ing which quality and integrity analysis of these samples contin-
ued for another 6 months and concluded in August 2016. Samples
for biobanking and clinical investigations were collected from
3357 and 3464 participants, respectively. The high-participation
rate was due to the availability of house visits and high standard
of participant engagement by the FRAs.
There is a slight preponderance of females in the cohort.
Participant ages range from 19 to 91 years (mean age: 42.81
years). The large majority of participants were of Sinhalese ethni-
city (92.94%). There was a high participation from urban areas,
and many respondents were unemployed and non-manual or
skilled manual workers. One percent of respondents had no edu-
cation, and the many participants (46%) had been schooled up to
General Certificate of Education (Ordinary Level). The COTASS 2
sociodemographic details of participants are detailed in Table 2.
Seventy-four percent of the participants are individual twins, as
one singleton was recruited for every pair of twins in COTASS
1. The total overall number of individual twins for DNA and
serum are 2485 and 2565 respectively, and 27% are opposite gen-
der twins. Zygosity characteristics are presented in Table 3.
Anthropometric measures, blood pressure, clinical investiga-
tions, and longitudinal survey data are linked to the SLTR-b.
Other data include heart rate variability data and actigraphy
data from two sub-studies within COTASS 2. Table 4 provides
details of all linked data, and Table 5 provides a list of selected
COTASS 2 mental and physical health characteristics of partici-
pants in the SLTR-b and associations or mean differences between
genders.
Discussion
‘Research infrastructure is an indispensable component of
research enterprise’ [13]. New knowledge and innovation can
only emerge from high-quality and accessible research
Table 1. COTASS 2 collected sample types, collection priority, volume, and purpose
Order of collection Type Volume (ml) Purpose
Fasting blood
1 EDTA 2.5 Glycated haemoglobin
2 Clot activator (SST) 3 Lipid profile, SGOTa, serum insulin, serum creatinine, hs-CRPb
3 Clot activator (SST) 5 Serum isolation for biobanking
4 Fluoride 2 Fasting blood sugar
5 EDTA 6 DNA isolation for biobanking
First morning urine
Sterile specimen bottle 10 Urine creatinine, urine micro albumin, urine albumin-creatinine ratio
aSerum glutamic oxaloacetic transaminase.
bHighly sensitive c reactive protein.
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infrastructures which include data resources, archives, and bio-
banks [14]. Biobanks are a valuable resource for creating advance-
ments in science through cutting-edge omics research. However,
there is a scarcity of biobanks in the South Asian region. This
may be due to a multitude of reasons including limitations in
infrastructure, capacity, and sociological or ethical issues less
common in Western settings. In addition, the lack of an overarch-
ing research culture in developing countries may be a systematic
barrier, resulting in limited new knowledge output and capacity
building within low- and middle-income countries. One of the
main aims of setting up the IRD was to overcome this by helping
to create an overarching research culture in Sri Lanka, and provid-
ing resources and infrastructure to local and international
scientists.
COTASS 1 data have been shared for higher degree pro-
grammes locally and internationally. Until now, some COTASS
2 data have already been pooled into the CODAtwins project
which is the largest international effort utilising the classical
twin design [15]. Similarly, the newly established biobank is
open for collaborative studies with academic institutions after
research protocols have been accepted by the SLTR-b steering
and ethics committees.
Human biospecimen collection for research and genetic stud-
ies are extremely sensitive matters especially in the developing
world [16–19]. Unethical collection and exportation of biospeci-
men during events such as the 2004 tsunami [20] have made
Sri Lankans apprehensive about biospecimen collection for
research purposes. Ethical appropriateness varies between set-
tings; understanding attitudes, views and beliefs of the commu-
nity and stakeholders related to genomics research and
biobanking is important [18]. We recently completed a qualitative
study on public understanding of genomic medicine and research
among SLTR-b participants [21]. Community engagement gener-
ates public trust which is of paramount importance. The IRD was
awarded grants from Wellcome Trust, UK (2009) and the Medical
Research Council, UK (2018) to engage twins in research through
cultural activities.
Ethics forms a crucial cornerstone in the SLTR-b. Beliefs and
values of our local communities played a major role in the
method and types of biospecimens collected and stored, all of
which must be taken into consideration. The IRD established
policies and guidelines for the Sri Lankan Twin Registry [12]
which conform to accepted international standards in genomic
studies. The IRD’s policy on human biospecimens is to analyse
the data within a national institution or laboratory if the necessary
infrastructure and technology exists. To address these concerns,
the IRD’s genetics laboratory was established during COTASS 1
as a strategic accomplishment from an ethical and infrastructure
point of view [22], thereby avoiding the necessity for exportation
biospecimens abroad. Broad consent was not obtained from
COTASS 2 participants for biobanking. Therefore, any new








Characteristics n % n %
Twin status
Singleton 872 25.88 899 25.95
Twin (individual) 2485 74.02 2565 74.05
Gender
Female 1895 56.45 1958 56.52
Male 1462 43.55 1506 43.48
Age
19–29 years 719 21.42 742 21.42
30–39 years 863 25.71 898 25.92
40–49 years 718 21.39 741 21.39
50–59 years 580 17.28 596 17.21
60–69 years 314 9.35 320 9.24
70+ years 163 4.86 167 4.82
Ethnicitya
Sinhala 3093 92.94 3186 92.83
Tamil 103 3.09 106 3.09
Muslim 118 3.55 126 3.67
Other 14 0.42 14 0.41
Urbanicity
Rural 1339 39.89 1392 40.18




1432 43.33 1479 43.39
Elementary occupations 285 8.62 288 8.45
Non-manual or skilled
manual workers
1335 40.39 1378 40.42
Managers or professionals 253 7.66 264 7.74
Education levela
No education 38 1.15 39 1.14
Grade 1–5 235 7.09 236 6.91
Grade 6 up to G.C.E. (O/L)b 1530 46.18 1571 45.99
Completed G.C.E. (O/L)
Exam
527 15.91 548 16.04
Up to or passed G.C.E.
(A/L)c Exam
758 22.88 788 23.07
University or higher 225 6.79 234 6.85
aContains missing data.
bGeneral Certificate of Education (ordinary level).
cGeneral Certificate of Education G.C.E. (advanced level).
Table 3. Zygosity characteristics of twins (complete and incomplete pairs) of
the SLTR-b
Zygosity DNA (%) Serum n (%)
Monozygotic females 605 (24.35) 621 (24.21)
Monozygotic males 467 (18.79) 483 (18.83)
Dizygotic females 405 (16.30) 421 (16.41)
Dizygotic males 316 (12.72) 325 (12.67)
Dizygotic opposite gender 692 (27.85) 715 (27.88)
Total 2485 (100.00) 2565 (100.00)
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studies using SLTR-b specimens will require new ethical approval
and consent from study participants as well.
The main strengths of the SLTR-b include the use of the twin
design with a large population-based collection of DNA and
serum from twins and singletons. Biospecimens are linked to a
variety of clinical biomarkers, physical measures, survey data on
common mental disorders, other data, and a comprehensive set
of confounders. We have been able to cover a wide age range,
Table 4. Types of data linked to the SLTR-b from the longitudinal COTASS study






Sociodemographic data Sociodemographic questionnaire Sociodemographic questionnaire 3357 3464
Depression Lifetime version of WHO-CIDIa Section E 12-month version of section E of the
WHO-CIDI
3329 3433
Beck Depression Inventory II 3312 3416
Post-traumatic stress
disorder
WHO-CIDI Section K 17 items PTSD Civilian Checklist 3326 3430
Anxiety WHO-CIDI Section D Generalised Anxiety Disorder 7 item 3323 3427
Somatic symptoms Bradford Somatic Inventory Bradford Somatic Inventory 3357 3464
Fatigue Chalder Fatigue Scale Chalder Fatigue Scale 3357 3464
Tobacco use WHO-CIDI Section B Tobacco Use questionnaire 3357 3464
Alcohol use WHO-CIDI Section J Alcohol Use Disorders Identification Test 3326 3430
Life events The list of threatening experiences The list of threatening experiences 3324 3428
Health and well-being Short Form-36 Health Survey Short Form 36 Health Survey 3329 3442
Twin zygosity Zygosity determination questionnaire Zygosity determination questionnaire 2485 2565
Closeness of twins Not done Closeness of twins questionnaire 2438 2515
Environmental stressors Childhood experience of care and abuse
questionnaireb
Not done 3362 3362
Suicidal ideations Suicidal ideations questionnaire Not done 3362 3362
Traumatic events War and tsunami questionnaire Not done 3362 3362
Social support Not done Multi-dimensional support scale
questionnaire
3323 3427
Eating disorders Not done Eating disorders questionnaireb 3329 3433
Dietary habits Not done Diet and frequency of food groupsc 3338 3442
Physical illnesses Not done A checklist of physical illnesses 3327 3431
Physical activity Not done International Physical Activity
Questionnaire
3312 3416
Sleep Not done Pittsburgh sleep quality index 3329 3433
Other
Biochemistry Not done Clinical urine tests 3352 3459
Clinical blood tests 3357 3464
Anthropometric
measurements
Not done Height, sitting height, weight, waist
circumference
3330 3437
Cardiovascular assessment Not done Resting blood pressure 3333 3440
Heart rate variability datad ϕ♂ 256 266
Sleep and activity
monitoring
Not done Actigraphye ϕ 214 220
aWorld Health Organisation – Composite International Diagnostic Interview.
bThe Dutch Eating Behaviour Questionnaire and the Three-Factor Eating Questionnaire were adopted for this eating disorders questionnaire.
cA questionnaire to measure the frequency of consumption of a comprehensive list of food groups in Sri Lanka.
dRecordings done on a Schiller Medilog AR12 Plus Holter Recorder at 1000 Hz.
eData collected using Phillips Actiwatch Spectrum.
ϕ Data from twins only.
♂ Data from males only.
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Table 5. Selected COTASS 2 health characteristics linked to the DNA in the SLTR-b and associations or mean differences between genders
Females Males
χ2/t-test
p value%/mean (n) %/mean (n)
Mental health
Depressive symptoms
None to mild 55.28% (1670) 44.72% (1351) <0.001
Moderate to severe 68.87% (208) 31.13% (94)
PTSD
No 56.19% (1785) 43.81% (1392) 0.019
Symptomatic 65.63% (105) 34.38% (55)
Anxiety
None to mild 54.93% (1598) 45.07% (1311) <0.001
Moderate to severe 68.24% (290) 31.76% (135)
Substance use
Smoking status
Doesn’t smoke 64.87% (1898) 35.13% (1028) <0.001
Current smoker 1.35% (6) 98.65% (437)
Alcohol use
No misuse 64.94% (1889) 35.06% (1020) <0.001
Misuse 0.23% (1) 99.77% (427)
Blood pressure
Systolic (mmHg) 114 (1888) 119 (1455) <0.001
Diastolic (mmHg) 75 (1888) 77 (1455) 0.0002
Anthropometry
Height (cm) 151.46 (1887) 165.41 (1453) <0.001
Weight (kg) 56.19 (1888) 62.82 (1453) <0.001
Waist Circumference (cm) 90.99 (1886) 86.59 (1452) <0.001
BMI (kg/m2) 24.46 (1886) 22.89 (1453) <0.001
Biochemistry
Serum creatinine (mg/dl) 0.74 (1904) 0.98 (1465) <0.001
Total cholesterol (mg/dl) 200.90 (1904) 198.61 (1465) 0.1053
Low-density lipoprotein (mg/dl) 127.31 (1904) 123.02 (1465) 0.0005
Very low-density lipoprotein (mg/dl) 22.42 (1904) 28.69 (1465) <0.001
High-density lipoprotein (mg/dl) 51.18 (1904) 46.89 (1465) <0.001
Triglycerides (mg/dl) 113.06 (1904) 147.36 (1465) <0.001
Total cholesterol/HDL ratio 4.03 (1904) 4.36 (1465) <0.001
SGOT (U/l) 22.73 (1904) 29.43 (1465) <0.001
Serum insulin (uU/ml) 13.45 (1902) 13.07 (1465) 0.5618
Ultra-sensitive c-reactive protein (mg/l) 3.60 (1904) 2.95 (1465) 0.0018
Fasting blood sugar (mg/dl) 108.49 (1904) 106.29 (1465) 0.1268
HbA1c (%) 6.05 (1904) 5.90 (1465) 0.0019
Urine creatinine (mg/dl) 84.12 (1900) 128.23 (1464) <0.001
Urine microalbumin (mg/l) 17.59 (1900) 22.35 (1464) 0.0195
Urine microalbumin/creatinine (mg of albumin/g) 34.63 (1900) 30.95 (1464) 0.6048
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and the younger age groups provide an opportunity to understand
disease development over future follow-up studies of COTASS.
Weaknesses include the lack of clinical data from COTASS 1,
and limited ethnic diversity. The cohort size of the SLTR-b is rela-
tively small in comparison with other international biobanks such
as the UK Biobank [23]. However, the SLTR-b was a component
within COTASS 2, and therefore we believe we have done justice
to the limited available funding. The biobank has limited geo-
graphic coverage (Colombo district only) and may limit
generalisability to other populations.
In 2019, we received a Medical Research Council, UK grant
to conduct a pilot study using the COTASS cohort (and their
children) to disentangle genetic and environmental components
of intergenerational risk transmission of nutritional choices on
risk factors for cardio vascular disease. This is the first of its
kind in a low- and middle-income country, and will use a
children-of-twins design to identify the extent to which the asso-
ciation between parental and offspring nutrition is due to genetic
and environmental transmission. The full grant is being applied
for in 2020 and we shall be using DNA from the SLTR-b for
GWAS to answer our research questions as well.
To conclude, the SLTR-b is a unique data-rich resource com-
prising genomic DNA and serum of twins and a matched sample
of non-twins from Colombo, Sri Lanka. We have shown that
large-scale research infrastructure development is possible in
low- and middle-income countries through North–South colla-
borations. This is the ‘first of its kind’ biobank establishment in
South Asia which will allow us to answer complex research ques-
tions, whereas aiming to address gaps in health and genetics
research. It will provide opportunities for further academic colla-
borations local and internationally, and capacity building of
future research leaders in twin and omics research. The future
goal of the IRD is to create a nationally representative repository
of biospecimens for use in innovative epidemiological research
providing new insights into diseases burdening the region.
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